Eritoran Tetrasodium

Description: Eritoran Tetrasodium, a TLR4 receptor antagonist, is used potentially for the treatment of type 2 diabetes. Target: Others. Smiles: [Na].CCCCCCCCCC CC(=O)CC(=O)N[C@H]1[C@@H](OP(O)(O)=O)O[C@H](CO[C@@H]2O[C@H](COC)[C@@H](OP(O)(O)=O)[C@H](OCC[C@@H](CCCCCCC)OC)[C@H]2NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](O)[C@@H]1OCCCCCCCCCC. References: Mcdonald KA, Huang H, Tohme S, Loughran P, Ferrero K, Billiar T, Tsung A. Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling. Mol Med. 2015 Mar 13,20:639-48. doi: 10.2119/molmed.2014.00076. PubMed PMID: 25375408, PubMed Central PMCID: PMC4365061.